MCID: VLV011
MIFTS: 51

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15 17
Candidiasis of Vulva and Vagina 12 32
Candidiasis, Vulvovaginal 43 71
Candidiasis Vulvovaginal 54
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12
Candidal: Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 34 112.1
MeSH 43 D002181
NCIt 49 C2914
SNOMED-CT 67 72605008
ICD10 32 B37.3
UMLS 71 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Other names for this infection are "vaginal candidiasis," "vulvovaginal candidiasis," or "candidal vaginitis."

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis of vulva and vagina, is related to candida glabrata and vaginitis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Miconazole and Dequalinium have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and cervix, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 74 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 333, show less)
# Related Disease Score Top Affiliating Genes
1 candida glabrata 31.5 SKAP2 IFNG
2 vaginitis 31.0 TLR2 LAP3 DEFB4A CCR6
3 vulvar vestibulitis syndrome 30.7 NLRP3 MBL2 IL1RN
4 cervicitis 30.5 TLR2 IL2 DEFB4A
5 bacterial vaginosis 30.4 TLR2 MBL2 LAP3 IL4 IL1RN DEFB4A
6 amyotrophic lateral sclerosis 3 30.4 SKAP2 CLEC7A CCR6
7 urethritis 30.3 TLR2 DEFB4A DEFA5
8 candidiasis 30.3 TLR2 SKAP2 MBL2 IL4 IL2 IFNG
9 immunoglobulin alpha deficiency 30.0 MBL2 CD79A CCR6
10 cutaneous candidiasis 29.7 CLEC7A CCR6 CARD9
11 acquired immunodeficiency syndrome 29.6 IL2 IFNG CD79A CCR6
12 dermatophytosis 29.4 DEFB4A CLEC7A CCR6 CARD9
13 immune deficiency disease 29.3 MBL2 IL4 IL2 IFNG CD79A CCR6
14 oral candidiasis 29.0 SKAP2 IL1RN DEFB4A DEFB1 CLEC7A CCR6
15 exanthem 28.8 NLRP3 IL2 IL1RN F2 CCR6
16 chronic mucocutaneous candidiasis 28.6 TLR2 IL4 IFNG CLEC7A CCR6 CARD9
17 vaginal disease 28.6 TLR2 SKAP2 IL2 DEFB4A CLEC7A CCR6
18 skin disease 28.6 TLR2 IL4 IL2 IFNG DEFB4A CD79A
19 bacterial infectious disease 28.1 TLR2 MBL2 LCN2 IL1RN IFNG DEFB4A
20 vulvovaginitis 10.9
21 vaginal discharge 10.8
22 immunoglobulin g deficiency 10.6 MBL2 CD79A
23 prosthetic joint infection 10.5 TLR2 MBL2
24 mycobacterium kansasii 10.5 TLR2 NLRP3
25 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.5 IL4 IL2
26 trichomoniasis 10.4
27 overgrowth syndrome 10.4
28 corneal abscess 10.4 DEFB4A DEFB1
29 fungal keratitis 10.4 TLR2 CLEC7A
30 haemophilus influenzae 10.4 TLR2 CLEC7A
31 mycobacterium abscessus 10.4 TLR2 NLRP3 CLEC7A
32 virus associated hemophagocytic syndrome 10.4 IL4 IL2
33 amebiasis 10.4 TLR2 IL4 CD79A
34 trichomonas vaginalis trichomoniasis 10.4
35 streptococcus pneumonia 10.4 TLR2 NLRP3 IL4
36 rheumatic heart disease 10.4 TLR2 MBL2 IL4
37 cryopyrin-associated periodic syndrome 10.3 NLRP3 IL1RN
38 jak3-deficient severe combined immunodeficiency 10.3 IL4 IL2
39 ige responsiveness, atopic 10.3
40 periapical granuloma 10.3 TLR2 IL4 IL2
41 neisseria meningitidis infection 10.3 TLR2 MBL2 IL1RN
42 tinea profunda 10.3 CLEC7A CARD9
43 agammaglobulinemia, x-linked 10.3 IL4 IL2 CD79A
44 fixed drug eruption 10.3 IL2 IFNG
45 chronic graft versus host disease 10.3 IFNG CD79A
46 b-cell growth factor 10.3 IL4 IFNG
47 cicatricial pemphigoid 10.2 IL4 IL1RN CD79A
48 inferolateral myocardial infarct 10.2 LCN2 GGT1
49 orofacial granulomatosis 10.2 IL4 IFNG CD79A
50 echinococcosis 10.2 TLR2 IFNG CD79A
51 neuroaspergillosis 10.2 TLR2 CLEC7A CARD9
52 clonorchiasis 10.2 IL2 IFNG CD79A
53 allergic bronchopulmonary aspergillosis 10.2 MBL2 IL4 IFNG
54 penicilliosis 10.2 CLEC7A CARD9
55 human immunodeficiency virus type 1 10.2
56 deficiency anemia 10.2
57 hyperglycemia 10.2
58 cytokine deficiency 10.2
59 septic arthritis 10.2 TLR2 IFNG DEFB4A
60 silicosis 10.2 NLRP3 IL4 IL1RN
61 mycoplasma pneumoniae pneumonia 10.2 TLR2 IL4 IFNG
62 familial mediterranean fever 10.2 TLR2 NLRP3 IL1RN
63 bacterial meningitis 10.2 TLR2 MBL2 IFNG
64 atopic keratoconjunctivitis 10.1 IL4 IL2 IFNG
65 keratoconjunctivitis 10.1 IL4 IL2 IFNG
66 plasmacytoma 10.1 IL4 IL2 CD79A
67 pneumoconiosis 10.1 NLRP3 IL4 IL1RN
68 endophthalmitis 10.1 TLR2 DEFB1 CARD9
69 mucocutaneous leishmaniasis 10.1 IL4 IL2 IFNG
70 acute graft versus host disease 10.1 IL4 IL2 IFNG
71 severe acute respiratory syndrome 10.1 MBL2 IL2 IFNG
72 erythema multiforme 10.1 IL4 IL2 IFNG
73 vertebrobasilar insufficiency 10.1 SKAP2 GGT1
74 herpes zoster 10.1 TLR2 IL2 IFNG
75 scrub typhus 10.1 TLR2 LCN2 IFNG
76 subacute sclerosing panencephalitis 10.1 IL4 IL2 IFNG
77 pyelonephritis 10.1 MBL2 LCN2 IFNG
78 allergic conjunctivitis 10.1 IL4 IL2 IFNG
79 autoimmune uveitis 10.1 IL4 IL2 IFNG
80 nickel allergic contact dermatitis 10.1 IL4 IFNG
81 filariasis 10.1 TLR2 IL2 IFNG
82 blau syndrome 10.1 TLR2 NLRP3 IL4 IL1RN
83 bronchiolitis 10.1 TLR2 IL4 IFNG
84 q fever 10.1 TLR2 MBL2 IL4 IFNG
85 aseptic meningitis 10.1 NLRP3 IL1RN IFNG
86 toxoplasmosis 10.0 TLR2 IL4 IFNG CD79A
87 meningococcemia 10.0 MBL2 IL1RN
88 rheumatic fever 10.0 TLR2 MBL2 IL2 IFNG
89 fibrosis of extraocular muscles, congenital, 1 10.0
90 lichen sclerosus et atrophicus 10.0
91 cystic fibrosis 10.0
92 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
93 allergic rhinitis 10.0
94 leukemia, acute lymphoblastic 3 10.0
95 chorioamnionitis 10.0
96 sexual disorder 10.0
97 anogenital venereal wart 10.0
98 iron deficiency anemia 10.0
99 postmenopausal atrophic vaginitis 10.0
100 dysentery 10.0
101 tinea pedis 10.0
102 diarrhea 10.0
103 somatization disorder 10.0
104 bacteriuria 10.0
105 chronic cervicitis 10.0
106 urticaria 10.0
107 dermatomycosis 10.0
108 mental depression 10.0
109 drug-induced hepatitis 10.0
110 iron metabolism disease 10.0
111 irritant dermatitis 10.0
112 leukorrhea 10.0
113 rhinitis 10.0
114 placenta disease 10.0
115 irritable bowel syndrome 10.0
116 depression 10.0
117 rapidly involuting congenital hemangioma 10.0
118 lmna-related cardiocutaneous progeria syndrome 10.0
119 food allergy 10.0 TLR2 IL4 IFNG
120 peptic ulcer disease 10.0 IL1RN DEFB4A DEFB1 DEFA5
121 microscopic colitis 10.0 IL4 IL2 IFNG CD79A
122 purpura 10.0 IL4 F2 CD79A
123 rubella 10.0 IL4 IL2 IFNG
124 spondyloarthropathy 10.0 IL4 IL2 IFNG
125 toxic oil syndrome 10.0 IL4 IFNG
126 conjunctivitis 10.0 NLRP3 IL4 IL2 IFNG
127 paracoccidioidomycosis 10.0 TLR2 IL4 IL2 IFNG
128 tetanus 10.0 IL4 IL2 IFNG CD79A
129 fasciitis 10.0 IL2 IL1RN IFNG
130 contact dermatitis 10.0 TLR2 IL4 IL2 IFNG
131 cutaneous leishmaniasis 10.0 TLR2 IL4 IL2 IFNG
132 visceral leishmaniasis 10.0 TLR2 IL4 IL2 IFNG
133 iga glomerulonephritis 10.0 MBL2 CD79A CCR6
134 papilledema 10.0 NLRP3 IL1RN F2
135 extrapulmonary tuberculosis 10.0 TLR2 MBL2 IL1RN IFNG
136 lichen planus 10.0 IL4 IL2 IFNG DEFB4A
137 trypanosomiasis 10.0 TLR2 IL4 IL2 IFNG
138 chagas disease 10.0 TLR2 IL4 IL2 IFNG
139 keratoconjunctivitis sicca 9.9 IL4 CD79A CCR6
140 chlamydia 9.9 TLR2 MBL2 IL4 IFNG CD79A
141 chronic fatigue syndrome 9.9 IL4 IL2 IFNG
142 otitis media 9.9 TLR2 MBL2 IL4 IFNG CD79A
143 gingival disease 9.9 TLR2 DEFB4A CCR6
144 pelvic inflammatory disease 9.9 TLR2 LCN2 IL2 IFNG
145 sporotrichosis 9.9 IFNG CLEC7A CD79A CARD9
146 genital herpes 9.9 TLR2 IL4 CCR6
147 aggressive periodontitis 9.9 TLR2 IL4 IL1RN DEFB4A DEFB1
148 hypersplenism 9.9 IL4 IFNG F2
149 hepatic tuberculosis 9.9 GGT1 F2
150 pleurisy 9.9 TLR2 IL2 IL1RN IFNG
151 vulvitis 9.9
152 common cold 9.9 TLR2 IL4 CCR6
153 phaeohyphomycosis 9.9 CLEC7A CARD9
154 ileus 9.9 IFNG F2 CD79A
155 inflammatory bowel disease 18 9.9 IL4 IL2 CCR6
156 respiratory allergy 9.9 TLR2 IL4 CCR6
157 autoimmune vasculitis 9.9 IL4 IL2 CCR6
158 anus disease 9.9 TLR2 IL2 CCR6
159 autoimmune disease of eyes, ear, nose and throat 9.9 IL4 IL2 CCR6
160 rectal disease 9.8 TLR2 IL2 CCR6
161 lymphatic system cancer 9.8 IL2 CD79A CCR6
162 pyelitis 9.8 TLR2 LCN2 CCR6
163 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.8 IL4 IL2 CCR6
164 pulmonary tuberculosis 9.8 TLR2 MBL2 IL4 IL2 IFNG
165 brucellosis 9.8 IL4 IL2 IL1RN IFNG
166 brain edema 9.8 IL2 IL1RN IFNG
167 smallpox 9.8 IL4 IL2 IL1RN IFNG
168 dengue hemorrhagic fever 9.8 IL4 IFNG F2
169 leishmaniasis 9.8 TLR2 MBL2 IL4 IL2 IFNG
170 bacterial pneumonia 9.8 TLR2 DEFB4A CCR6
171 alopecia areata 9.8 IL4 IL2 IL1RN IFNG
172 b cell deficiency 9.8 IL4 IL2 CCR6
173 combined t cell and b cell immunodeficiency 9.8 IL4 IL2 CCR6
174 neuromuscular junction disease 9.8 IL4 IL2 CCR6
175 gingivitis 9.8 TLR2 IL4 IL2 IFNG DEFB4A
176 mature b-cell neoplasm 9.8 IL2 CD79A CCR6
177 lepromatous leprosy 9.8 TLR2 IL4 IL2 IFNG DEFB1
178 hypotrichosis 1 9.8 IL4 IL2 CCR6
179 factor vii deficiency 9.8 IL2 GGT1 F2
180 takayasu arteritis 9.8 IL2 IL1RN F2
181 pyoderma 9.8 NLRP3 IL1RN CCR6
182 pyoderma gangrenosum 9.8 NLRP3 IL1RN CCR6
183 histoplasmosis 9.8 IFNG CLEC7A CCR6
184 blastomycosis 9.8 CLEC7A CCR6 CARD9
185 bacterial sepsis 9.8 TLR2 IL1RN CCR6
186 gastroenteritis 9.8 IL4 IL1RN IFNG
187 listeriosis 9.8 TLR2 MBL2 IL2 CCR6
188 cinca syndrome 9.8 NLRP3 IL1RN CCR6
189 obstructive jaundice 9.8 IL2 GGT1 F2
190 endocarditis 9.8 TLR2 IFNG F2
191 scleral disease 9.8 IL2 IL1RN CCR6
192 pars planitis 9.8 IL2 IL1RN CCR6
193 vernal conjunctivitis 9.7 IL4 IFNG CCR6
194 hair disease 9.7 IL4 IL2 CCR6
195 corneal disease 9.7 TLR2 NLRP3 CCR6
196 subcutaneous mycosis 9.7 CLEC7A CCR6 CARD9
197 proteasome-associated autoinflammatory syndrome 1 9.7 TLR2 NLRP3 IL4 IL1RN IFNG
198 acute cholangitis 9.7 IL1RN GGT1 F2
199 osteomyelitis 9.7 TLR2 NLRP3 IL4 IL1RN IFNG
200 hyper ige recurrent infection syndrome 1 9.7 CLEC7A CCR6 CARD9
201 alcoholic hepatitis 9.7 TLR2 GGT1 F2
202 nail disease 9.7 CLEC7A CCR6 CARD9
203 autoimmune polyendocrine syndrome type 1 9.7 CLEC7A CCR6 CARD9
204 peanut allergy 9.7 IL4 IFNG CCR6
205 juvenile rheumatoid arthritis 9.7 IL2 IL1RN IFNG
206 intermediate uveitis 9.7 IL2 IFNG CCR6
207 herpangina 9.7 TLR2 IL4 IL2 CCR6
208 meningoencephalitis 9.7 CD79A CCR6 CARD9
209 yellow fever 9.7 IL4 IL1RN CCR6
210 paranasal sinus disease 9.7 IL4 IFNG CCR6
211 extrinsic cardiomyopathy 9.7 TLR2 IL4 IL2 CCR6
212 common variable immunodeficiency 9.7 TLR2 MBL2 IL4 IL2 IFNG CD79A
213 meningitis 9.7 TLR2 NLRP3 MBL2 IL4 IL2 IFNG
214 leukocyte disease 9.7 IL4 IL2 CD79A CCR6
215 mastitis 9.7 TLR2 IL1RN CCR6
216 toxic shock syndrome 9.7 TLR2 IL4 IL2 IL1RN IFNG
217 reactive arthritis 9.7 TLR2 IFNG CCR6
218 sclerosing cholangitis 9.7 IL2 GGT1 F2
219 tonsillitis 9.7 TLR2 IL4 IL2 IFNG DEFB1 CD79A
220 hepatitis e 9.7 IFNG GGT1 F2
221 pulmonary sarcoidosis 9.7 IL2 IFNG CCR6
222 central nervous system vasculitis 9.6 IL1RN IFNG CCR6
223 coccidioidomycosis 9.6 MBL2 CLEC7A CCR6 CARD9
224 biliary atresia 9.6 IFNG GGT1 F2
225 pulmonary disease, chronic obstructive 9.6 TLR2 IL4 DEFB1 CCR6
226 folliculitis 9.6 IL4 IFNG DEFB4A CCR6
227 autoimmune disease of blood 9.6 IL2 F2 CCR6
228 peritonitis 9.6 TLR2 NLRP3 IL4 IFNG F2
229 spondylitis 9.6 IL1RN IFNG CCR6
230 chromoblastomycosis 9.6 IL4 CLEC7A CCR6 CARD9
231 temporal arteritis 9.6 IL1RN IFNG CCR6
232 urinary tract obstruction 9.5 LCN2 GGT1 CCR6
233 inflammatory bowel disease 1 9.5 TLR2 DEFB4A CCR6 CARD9
234 tuberculoid leprosy 9.5 IL4 IL2 IFNG CCR6
235 periodontitis 9.5 TLR2 IL4 IL1RN IFNG DEFB4A DEFB1
236 autoimmune gastritis 9.5 IL4 IL2 IFNG CCR6
237 lichen disease 9.5 IL4 IL2 IFNG CCR6
238 chickenpox 9.5 IL4 IL2 IFNG CCR6
239 posterior uveitis 9.5 IL4 IL2 IFNG CCR6
240 autoimmune disease of endocrine system 9.5 IL4 IL2 IFNG CCR6
241 crohn's colitis 9.5 IL2 IFNG DEFA5 CCR6
242 aphthous stomatitis 9.5 TLR2 NLRP3 IL4 IL2 IL1RN IFNG
243 stomatitis 9.5 TLR2 NLRP3 IL4 IL2 IL1RN IFNG
244 idiopathic interstitial pneumonia 9.5 IL4 IFNG CCR6
245 sezary's disease 9.5 IL4 IL2 IFNG CCR6
246 invasive aspergillosis 9.5 TLR2 MBL2 IFNG CLEC7A CCR6
247 cutaneous t cell lymphoma 9.5 IL4 IL2 IFNG CCR6
248 lymphopenia 9.5 IL4 IL2 IFNG CCR6
249 sebaceous gland disease 9.5 TLR2 NLRP3 IL1RN DEFB4A CCR6
250 cryptococcosis 9.5 MBL2 IL4 IFNG CLEC7A CCR6
251 demyelinating disease 9.5 IL4 IL2 IFNG CCR6
252 blood coagulation disease 9.5 IL2 F2 CCR6
253 rheumatic disease 9.5 MBL2 IL1RN IFNG CCR6
254 neurofibromatosis, type ii 9.5 TLR2 IL1RN DEFB4A DEFB1 CCR6
255 scleritis 9.5 IL4 IL1RN IFNG CCR6
256 mucormycosis 9.4 IFNG CLEC7A CCR6 CARD9
257 gastritis 9.4 IL1RN DEFB4A DEFB1 DEFA5 CCR6
258 hepatic vascular disease 9.4 GGT1 F2 CCR6
259 acute cystitis 9.4 TLR2 LCN2 F2 CCR6
260 pleural disease 9.4 IFNG F2 CCR6
261 lymphatic system disease 9.4 IL4 IL2 IFNG CD79A CCR6
262 sarcoidosis 1 9.4 IL2 IL1RN IFNG CCR6
263 autoimmune disease of urogenital tract 9.4 GGT1 F2 CCR6
264 hepatitis b 9.4 TLR2 MBL2 IFNG GGT1 F2
265 coccidiosis 9.4 TLR2 IL4 IL2 IFNG CCR6
266 nasal cavity disease 9.4 TLR2 IL4 IL2 IFNG CCR6
267 lymph node disease 9.4 TLR2 IL4 IL2 IFNG CCR6
268 nose disease 9.4 TLR2 IL4 IL2 IFNG CCR6
269 commensal bacterial infectious disease 9.4 TLR2 IL4 IL2 IFNG CCR6
270 parasitic helminthiasis infectious disease 9.4 TLR2 IL4 IL2 IFNG CCR6
271 testicular disease 9.4 TLR2 IL4 IL2 IFNG CCR6
272 vein disease 9.4 GGT1 F2 CCR6
273 leprosy 3 9.4 TLR2 IL4 IL2 IFNG CCR6
274 parasitic protozoa infectious disease 9.4 TLR2 IL4 IL2 IFNG CCR6
275 autoimmune disease of musculoskeletal system 9.4 TLR2 IL4 IL2 IFNG CCR6
276 bronchial disease 9.4 TLR2 IL4 IL2 IFNG CCR6
277 primary bacterial infectious disease 9.4 TLR2 IL4 IL2 IFNG CCR6
278 autoimmune disease of central nervous system 9.4 TLR2 IL4 IL2 IFNG CCR6
279 upper respiratory tract disease 9.4 TLR2 IL4 IL2 IFNG CCR6
280 immune system disease 9.3 TLR2 IL4 IL2 IFNG CCR6
281 peripheral nervous system disease 9.3 TLR2 IL4 IL2 IFNG CCR6
282 dermatitis 9.3 TLR2 IL4 IL2 IFNG CCR6
283 myeloma, multiple 9.3 IL4 IL2 IFNG CD79A CCR6
284 hepatitis a 9.3 IL4 IL2 IFNG GGT1 F2
285 mycobacterium tuberculosis 1 9.3 TLR2 MBL2 IL4 IFNG CLEC7A CCR6
286 schistosomiasis 9.3 IL4 IL2 IFNG GGT1 F2
287 arthritis 9.3 TLR2 IL4 IL1RN IFNG CCR6
288 leptospirosis 9.3 TLR2 LCN2 IL4 IL2 IFNG F2
289 human immunodeficiency virus infectious disease 9.3 MBL2 IL4 IL2 IFNG CD79A CCR6
290 pulmonary fibrosis, idiopathic 9.2 TLR2 IL4 IL1RN IFNG CCR6
291 conjunctival disease 9.2 TLR2 NLRP3 IL4 IL2 IL1RN CCR6
292 uveal disease 9.2 IL4 IL2 IL1RN IFNG CCR6
293 relapsing-remitting multiple sclerosis 9.2 IL4 IL2 IL1RN IFNG CCR6
294 allergic hypersensitivity disease 9.2 TLR2 IL4 IL2 IFNG CD79A CCR6
295 ulcerative colitis 9.2 IL4 IL2 IL1RN IFNG CCR6
296 autoimmune hepatitis 9.2 IL4 GGT1 F2
297 severe combined immunodeficiency 9.2 IL4 IL2 IL1RN IFNG CCR6
298 dermatitis, atopic 9.2 TLR2 IL4 IL2 IFNG DEFB4A CCR6
299 colitis 9.1 TLR2 IL4 IL2 IFNG DEFA5 CCR6
300 viral hepatitis 9.1 TLR2 IL4 IL2 IFNG GGT1 F2
301 psoriasis 9.1 TLR2 IL4 IL2 IFNG DEFB4A CCR6
302 typhoid fever 9.1 IFNG GGT1 F2 CCR6
303 autoimmune disease of gastrointestinal tract 9.1 IL4 IL2 IFNG F2 CCR6
304 hypersensitivity reaction type iv disease 9.1 TLR2 IL4 IL2 IL1RN IFNG CCR6
305 psoriatic arthritis 9.1 TLR2 IL4 IL2 IL1RN IFNG CCR6
306 salmonellosis 9.0 TLR2 NLRP3 IFNG DEFB4A DEFB1 DEFA5
307 connective tissue disease 9.0 TLR2 IL4 IL2 IL1RN IFNG CCR6
308 primary biliary cirrhosis 9.0 MBL2 IL4 IL2 IFNG GGT1 F2
309 aspergillosis 9.0 TLR2 MBL2 IL4 IL1RN IFNG CLEC7A
310 crohn's disease 9.0 TLR2 NLRP3 IL4 IL2 IFNG DEFA5
311 celiac disease 1 9.0 TLR2 LAP3 IL4 IL2 IFNG CD79A
312 viral infectious disease 9.0 TLR2 IL4 IL2 IFNG GGT1 CCR6
313 autoimmune disease 8.9 MBL2 IL4 IL2 IL1RN IFNG CD79A
314 splenic disease 8.9 TLR2 IL4 IL2 IFNG F2 CCR6
315 multiple sclerosis 8.9 TLR2 MBL2 IL4 IL2 IL1RN IFNG
316 diabetes mellitus, insulin-dependent 8.9 TLR2 IL4 IL2 IL1RN IFNG CD79A
317 bone inflammation disease 8.9 TLR2 NLRP3 IL4 IL2 IL1RN IFNG
318 body mass index quantitative trait locus 11 8.8 TLR2 NLRP3 LCN2 IL4 GGT1 CCR6
319 primary systemic mycosis 8.8 TLR2 IL4 IL2 IFNG CLEC7A CCR6
320 myocardial infarction 8.8 TLR2 LCN2 IL4 IL1RN IFNG F2
321 rheumatoid arthritis 8.7 TLR2 MBL2 IL4 IL2 IL1RN IFNG
322 pneumonia 8.7 TLR2 NLRP3 MBL2 IL4 IL2 IL1RN
323 eye disease 8.7 TLR2 IL4 IL2 IL1RN IFNG DEFB4A
324 diabetes mellitus, noninsulin-dependent 8.7 TLR2 NLRP3 LCN2 IL4 IL1RN GGT1
325 opportunistic mycosis 8.7 TLR2 SKAP2 IL4 IL2 IFNG CLEC7A
326 thrombocytopenia 8.7 TLR2 IL4 IL2 IL1RN IFNG GGT1
327 hypertension, essential 8.7 TLR2 NLRP3 LCN2 IL4 IL2 IFNG
328 diabetes mellitus 8.5 TLR2 LCN2 IL4 IL2 IL1RN IFNG
329 behcet syndrome 8.3 TLR2 NLRP3 MBL2 IL4 IL2 IL1RN
330 malaria 8.2 TLR2 NLRP3 MBL2 LCN2 IL4 IL2
331 asthma 8.1 TLR2 NLRP3 MBL2 IL4 IL2 IL1RN
332 systemic lupus erythematosus 7.6 TLR2 MBL2 LCN2 IL4 IL2 IL1RN
333 inflammatory bowel disease 7.0 TLR2 NLRP3 LCN2 IL4 IL2 IL1RN

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (showing 12, show less)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 CARD9 CCR6 CD79A CLEC7A F2 GGT1
2 homeostasis/metabolism MP:0005376 10.1 CARD9 CCR6 CD79A CLEC7A F2 GGT1
3 immune system MP:0005387 10.06 CARD9 CCR6 CD79A CLEC7A F2 GGT1
4 liver/biliary system MP:0005370 9.5 CD79A IFNG IL2 IL4 LCN2 NLRP3
5 renal/urinary system MP:0005367 9.23 CD79A GGT1 IFNG IL4 LCN2 MBL2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 56, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Dequalinium Approved, Investigational Phase 4 6707-58-0
3
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6 Antifungal Agents Phase 4
7 Cytochrome P-450 Enzyme Inhibitors Phase 4
8 Hormone Antagonists Phase 4
9 Steroid Synthesis Inhibitors Phase 4
10 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
11
Metronidazole Approved Phase 3 443-48-1 4173
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
13
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
14
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
15
Secnidazole Approved Phase 3 3366-95-8
16
Terconazole Approved Phase 3 67915-31-5 441383
17
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
18 Antiprotozoal Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Anti-Bacterial Agents Phase 3
21 Liposomal amphotericin B Phase 3
22 Clindamycin palmitate Phase 3
23 Clindamycin phosphate Phase 3
24 Alkylating Agents Phase 3
25 Cytochrome P-450 CYP3A Inhibitors Phase 3
26
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
27
Titanium dioxide Approved Phase 2 13463-67-7
28
Metformin Approved Phase 2 657-24-9 14219 4091
29
Canagliflozin Approved Phase 2 842133-18-0
30 Vaccines Phase 1, Phase 2
31 Immunologic Factors Phase 1, Phase 2
32 Rezafungin Phase 2
33 Gastrointestinal Agents Phase 1, Phase 2
34 Adjuvants, Immunologic Phase 1, Phase 2
35 Anti-Ulcer Agents Phase 1, Phase 2
36 Antacids Phase 1, Phase 2
37 HIV Protease Inhibitors Phase 2
38 Hypoglycemic Agents Phase 2
39
protease inhibitors Phase 2
40 Incretins Phase 2
41 Sitagliptin Phosphate Phase 2
42 Dipeptidyl-Peptidase IV Inhibitors Phase 2
43 Sodium-Glucose Transporter 2 Inhibitors Phase 2
44 Anti-Obesity Agents Phase 2
45 Anti-Infective Agents Phase 2
46 Acidophilus Phase 1
47
Butoconazole Approved 64872-76-0, 64872-77-1 47472
48
Itraconazole Approved, Investigational 84625-61-6 55283
49
Iron Approved, Experimental 7439-89-6, 15438-31-0 23925 27284
50 Trace Elements
51 Micronutrients
52
Hydroxyitraconazole
53 Nutrients
54 Bifidobacterium
55 Brewer's Yeast
56 Antibiotics, Antitubercular

Interventional clinical trials:

(showing 69, show less)
# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
2 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
6 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
7 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
8 Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management Completed NCT00353561 Phase 3 Boric;Fluconazole
9 A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis. Completed NCT01806623 Phase 3 Fluconazole
10 An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
12 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
13 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03734991 Phase 3 Ibrexafungerp;Placebo
14 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
15 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia. Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
16 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
17 Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
18 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
19 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03562156 Phase 3 VT-1161;Placebo
20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03561701 Phase 3 VT-1161;Placebo
21 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Recruiting NCT03987620 Phase 3 Ibrexafungerp;Placebo
22 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
23 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
24 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
25 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
26 Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
27 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis Completed NCT02267382 Phase 2 VT-1161;Placebo
28 A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis Completed NCT01891331 Phase 2 VT-1161;Fluconazole
29 A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
30 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
31 A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
32 Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
33 A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
34 A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
35 A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC) Completed NCT02866227 Phase 2 TOL-463;TOL-463
36 A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
37 A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm Completed NCT00642278 Phase 2 Canagliflozin (JNJ-28431754);Sitagliptin;Placebo
38 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects Completed NCT00650806 Phase 2 Canagliflozin (JNJ-28431754);Placebo
39 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
40 A Randomized, Double-Blind, Placebo-Controlled Trial Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) [SUBVert] Recruiting NCT03930745 Phase 2 TOL-463
41 A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
42 A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
43 A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers Completed NCT01067131 Phase 1
44 Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women. Completed NCT02730494 Phase 1
45 A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
46 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046
47 "A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis" Unknown status NCT00417365
48 Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Unknown status NCT02185456 Early Phase 1 750 mg metronidazole/ 200 mg miconazole vaginal suppository;Standard of care
49 A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
50 A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02888197
51 A Multi-center, Randomized, Investigator-blinded, Parallel-group Study, Designed to Evaluate the Safety and Clinical Equivalence of Terconazole Vaginal Suppositories, 80 mg (Test Product) and Terconazole Vaginal Suppositories, 80 mg (Reference Product) in the Treatment of Vulvovaginal Candidiasis Caused by Candida Species Completed NCT00803738 Terconazole Vaginal Suppository;Terazol Vaginal Suppository
52 Pilot Study Investigating Bacteria (Microbiota), Their By-products (Metabolome) and Environmental Toxins in Relation to Reproductive Health in Rwandan Women. Completed NCT02150655 Early Phase 1
53 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
54 Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices. Completed NCT02203942
55 Monthly Itraconazole Versus Classic Homeopathy for the Treatment of Recurrent Vulvovaginal Candidiasis: a Randomised Trial Completed NCT00895453 itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
56 Studie Van de Vaginale Microbiota en Het Potentieel Van Een Vaginale Zalf Met Probiotica Bij Vaginale Candidose Completed NCT03975569
57 Improving HIV Prevention and Sexual and Reproductive Health Care in High Risk Women in Rwanda Using Lessons Learnt From Previous Rinda Ubuzima Projects Completed NCT03045809
58 Vaginal Cytokines in Postmenopausal Women With Symptoms of Vulvovaginal Irritation Completed NCT01899612
59 Gynecological Health of Adult Women With Cystic Fibrosis: Positive Impact of the Implementation of an On-site Gynecological Consultation Completed NCT03892304
60 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1 Terazol or oral fluconazole for candidal vaginitis;Metronidazole or Clindamycin for Bacterial Vaginosis;Flagyl for definitively diagnosed vaginal trichomoniasis
61 Estudio epidemiológico de la evolución clínica y microbiológica en Pacientes Tratadas Por un Episodio Agudo de Candidiasis Vulvovaginal Recruiting NCT03064789
62 Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study Recruiting NCT02795845
63 Use of Probiotic for the Prevention of Re-occurrence Vaginal Candidiasis in Pregnant Women Recruiting NCT03940612
64 An Open-label Study to Evaluate Clinical Performance of Gedea Pessary in Adult Women With Vulvovaginal Candidiasis Active, not recruiting NCT03761628
65 Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M® Terminated NCT00915629
66 Evaluation of the Effect of Saccharomyces Cerevisiae on the Improvement of the Conventional Treatment for Vulvo-vaginal Infection to Candida Spp (Local Administration) Terminated NCT02859493
67 A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis Terminated NCT02345096
68 Microbiomic and Immunologic Profiling of Women With Antibiotic Induced Vaginal Candidiasis Terminated NCT01915251
69 Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia- A Prospective Study Withdrawn NCT01741948 Hormonal contraceptive

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


butoconazole
Butoconazole nitrate
Clotrimazole
Fluconazole
Gentian Violet
Itraconazole
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
NYSTATIN PWDR
terconazole
tioconazole

Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

40
Skin, Testes, Cervix, B Cells, Colon, Neutrophil, T Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(showing 1139, show less)
# Title Authors PMID Year
1
Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. 54 61
19910100 2010
2
Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. 54 61
18715406 2008
3
MBL2 genetic screening in patients with recurrent vaginal infections. 54 61
18211540 2008
4
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 54 61
17470593 2007
5
Mannose-binding lectin and vulvovaginal candidiasis. 54 61
16256117 2006
6
Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. 54 61
15825027 2005
7
Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. 54 61
12942410 2003
8
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. 61
31812702 2020
9
Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis. 61
31705810 2020
10
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2020
11
Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis. 61
31887870 2020
12
In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis. 61
31901238 2020
13
Copper IUD increases virulence of non-albicans Candida species isolated from women with vulvovaginal candidiasis. 61
31990231 2020
14
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans. 61
31860575 2020
15
Clinical Characteristics and Antifungal Susceptibility of Candida nivariensis from Vulvovaginal Candidiasis. 61
31694024 2020
16
In vitro anticandidal potency of Syzygium aromaticum (clove) extracts against vaginal candidiasis. 61
32020877 2020
17
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. 61
31972980 2020
18
Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study. 61
31748322 2020
19
Chitooligosaccharides and Thermostable Chitinase Against Vulvovaginal Candidiasis and Saprophyte Fungi: LC Mass Studies of Shrimp Shell Fermentation by Bacillus altitudinis. 61
31659402 2020
20
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis. 61
31965356 2020
21
Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. 61
31299136 2020
22
Soluble beta-glucan salecan improves vaginal infection of Candida albicans in mice. 61
31982527 2020
23
Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. 61
31502121 2020
24
Antifungal and Antivirulence Activities of Hydroalcoholic Extract and Fractions of Platonia insignis Leaves against Vaginal Isolates of Candida Species. 61
32013047 2020
25
New Technological Approach For Glycyrrethic Acid Oral And Topical Administration. 61
31878851 2019
26
Utilizing Liposomal Quercetin and Gallic Acid in Localized Treatment of Vaginal Candida Infections. 61
31861805 2019
27
Prospective Evaluation of Molecular Assays for Diagnosis of Vaginitis. 61
31694966 2019
28
Vulvovaginal candidiasis among symptomatic women of childbearing age attended at a Medical Analysis Laboratory in Franceville, Gabon. 61
31481349 2019
29
Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis. 61
31762516 2019
30
The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. 61
31446677 2019
31
The IL-17R/IL-22R signaling axis is dispensable for vulvovaginal candidiasis regardless of estrogen status. 61
31805183 2019
32
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. 61
30945022 2019
33
The effect of curcumin-based and clotrimazole vaginal cream in the treatment of vulvovaginal candidiasis. 61
31879636 2019
34
Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. 61
31663976 2019
35
Correction: Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. 61
31699752 2019
36
Cinnamaldehyde inhibits Candida albicans growth by causing apoptosis and its treatment on vulvovaginal candidiasis and oropharyngeal candidiasis. 61
31659418 2019
37
Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. 61
31451496 2019
38
A comparative analysis of protein virulence factors released via extracellular vesicles in two Candida albicans strains cultivated in a nutrient-limited medium. 61
31412284 2019
39
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. 61
31707496 2019
40
The Vaginal Microbiota and Behavioral Factors Associated With Genital Candida albicans Detection in Reproductive-Age Women. 61
31517769 2019
41
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. 61
29685081 2019
42
Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. 61
31845594 2019
43
Biodegradable cross-linked chitosan nanoparticles improve anti-Candida and anti-biofilm activity of TistH, a peptide identified in the venom gland of the Tityus stigmurus scorpion. 61
31349502 2019
44
Systematic analysis of protein expression in Candida albicans exposed to farnesol. 61
31503056 2019
45
Should we absolutely reject the hypothesis that epithelium-based Candida biofilms contribute to the pathogenesis of human vulvovaginal candidiasis? 61
31283906 2019
46
Sunlight exposure, consumption of vitamin D-rich foods and vulvovaginal candidiasis in an African population: a prevalence case-control study. 61
31636409 2019
47
Association of sexual function and psychological symptoms (depression, anxiety and stress) in women with recurrent vulvovaginal candidiasis 61
31640303 2019
48
Bacterial vaginosis, vulvovaginal candidiasis and trichomonal vaginitis among reproductive-aged women seeking primary healthcare in Sana'a city, Yemen. 61
31640583 2019
49
Diversity of vaginal microbiome and metabolome during genital infections. 61
31575935 2019
50
Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis. 61
31757595 2019
51
The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. 61
31330226 2019
52
Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring. 61
31315951 2019
53
Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis. 61
31158491 2019
54
Influence of recurrent vulvovaginal candidiasis on quality of life issues. 61
31270690 2019
55
Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota? 61
31212037 2019
56
Study on the prevalence and factors associated to vulvodynia in Spain. 61
31260857 2019
57
Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. 61
31547803 2019
58
Antifungal and Antivirulence Activity of Vaginal Lactobacillus Spp. Products against Candida Vaginal Isolates. 61
31547398 2019
59
Sweet Relief: Determining the Antimicrobial Activity of Medical Grade Honey Against Vaginal Isolates of Candida albicans. 61
31505796 2019
60
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis. 61
31106557 2019
61
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. 61
30656691 2019
62
Evaluation of reliability of self-collected vaginal swabs over physician-collected samples for diagnosis of bacterial vaginosis, candidiasis and trichomoniasis, in a resource-limited setting: a cross-sectional study in India. 61
31462459 2019
63
Fungal Diseases in Taiwan-National Insurance Data and Estimation. 61
31438643 2019
64
Estimated Burden of Fungal Infections in Namibia. 61
31426392 2019
65
Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. 61
30544194 2019
66
Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. 61
31132175 2019
67
Questions remain regarding the presence of fungal species biofilm in women with vulvovaginal candidiasis. 61
31029662 2019
68
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. 61
30893271 2019
69
The Burden of Serious Fungal Infections in Tajikistan. 61
31330914 2019
70
The Burden of Serious Fungal Infections in Kyrgyzstan. 61
31331088 2019
71
Probiotics for oral and vulvovaginal candidiasis: A review. 61
31112355 2019
72
Candida albicans vaginitis in a murine model is reduced by polypeptide-enriched Gastrodia elata extracts. 61
31373210 2019
73
Reactional changes in short-term levonorgestrel-releasing intrauterine system (lng-ius) use. 61
31340317 2019
74
Hormones modulate Candida vaginal isolates biofilm formation and decrease their susceptibility to azoles and hydrogen peroxide. 61
31254346 2019
75
Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. 61
31031172 2019
76
Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. 61
30968320 2019
77
A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. 61
31189718 2019
78
Recurrent vulvo-vaginal candidiasis in Abidjan (Côte d'Ivoire): Aetiology and associated factors. 61
31010729 2019
79
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. 61
30885896 2019
80
Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. 61
31122991 2019
81
Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis. 61
31117966 2019
82
[Changes of local vaginal immune regulation in rats infected with vulvovaginal candidiasis]. 61
31154715 2019
83
Estimated Burden of Serious Fungal Infections in Ghana. 61
31083531 2019
84
Antifungal activity of analogues of antimicrobial peptides isolated from bee venoms against vulvovaginal Candida spp. 61
30753486 2019
85
Virulence and antifungal susceptibility of microsatellite genotypes of Candida albicans from superficial and deep locations. 61
31037772 2019
86
Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis. 61
30685805 2019
87
Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment. 61
30890237 2019
88
Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans. 61
31148560 2019
89
Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. 61
30663184 2019
90
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. 61
30565745 2019
91
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. 61
29846682 2019
92
NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice. 61
30996274 2019
93
Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. 61
30562603 2019
94
Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model. 61
30689833 2019
95
Candida glabrata Fungemia Following Robotic Total Laparoscopic Hysterectomy and Bilateral Salpingo-oophorectomy in a Patient with Recurrent Vulvovaginitis: A Case Report. 61
31187014 2019
96
Alternative and complementary therapies for vulvovaginal candidiasis. 61
30269301 2019
97
Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. 61
30925872 2019
98
In Vivo Applicability of Neosartorya fischeri Antifungal Protein 2 (NFAP2) in Treatment of Vulvovaginal Candidiasis. 61
30478163 2019
99
Miconazole loaded chitosan-based nanoparticles for local treatment of vulvovaginal candidiasis fungal infections. 61
30481701 2019
100
Is mannose-binding lectin serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? 61
29110332 2019
101
Biofilms and vulvovaginal candidiasis. 61
30447520 2019
102
Aerobic vaginitis in late pregnancy and outcomes of pregnancy. 61
30467614 2019
103
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. 61
30184181 2019
104
Microsatellite Typing and Antifungal Susceptibility of Candida glabrata Strains Isolated From Patients With Candida Vaginitis. 61
31417505 2019
105
A Role for Yeast/Pseudohyphal Cells of Candida albicans in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis. 61
31803172 2019
106
Targeting the Aryl Hydrocarbon Receptor With Indole-3-Aldehyde Protects From Vulvovaginal Candidiasis via the IL-22-IL-18 Cross-Talk. 61
31681274 2019
107
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. 61
29361177 2019
108
Local Probiotic Lactobacillus crispatus and Lactobacillus delbrueckii Exhibit Strong Antifungal Effects Against Vulvovaginal Candidiasis in a Rat Model. 61
31139166 2019
109
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. 61
30621597 2019
110
The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. 61
30101450 2019
111
RAFT-Derived Polymethacrylates as a Superior Treatment for Recurrent Vulvovaginal Candidiasis by Targeting Biotic Biofilms and Persister Cells. 61
31787962 2019
112
SNPs in 3'-UTR region of MBL2 increases susceptibility to recurrent vulvovaginal infections by altering sMBL levels. 61
30482481 2019
113
Functional Synergy Of Antimicrobial Peptides And Chlorhexidine Acetate Against Gram-Negative/Gram-Positive Bacteria And A Fungus In Vitro And In Vivo. 61
31686873 2019
114
Estimated burden of serious human fungal diseases in Turkey. 61
30107069 2019
115
Effect of Shikonin Against Candida albicans Biofilms. 61
31156594 2019
116
Probiotics and vaginal microecology: fact or fancy? 61
30704451 2019
117
Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. 61
30595144 2019
118
Emergence of Vulvovaginal Candidiasis among Lebanese Pregnant Women: Prevalence, Risk Factors, and Species Distribution. 61
31467477 2019
119
Effect of Perillaldehyde on Prophylaxis and Treatment of Vaginal Candidiasis in a Murine Model. 61
31333606 2019
120
Comparative Analysis of the Capacity of the Candida Species To Elicit Vaginal Immunopathology. 61
30249743 2018
121
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. 61
29931589 2018
122
Electrosprayed chitosan microcapsules as delivery vehicles for vaginal phytoformulations. 61
30241838 2018
123
Competition of Candida glabrata against Lactobacillus is Hog1 dependent. 61
30112857 2018
124
Etiology of Vaginal/Cervical Discharge Syndrome: Analysis of Data from a Referral Laboratory in Eastern India. 61
30504977 2018
125
Development and anti-Candida evaluation of the vaginal delivery system of amphotericin B nanosuspension-loaded thermogel. 61
29378463 2018
126
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. 61
29790255 2018
127
Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics. 61
30248002 2018
128
Global burden of recurrent vulvovaginal candidiasis: a systematic review. 61
30078662 2018
129
Concerns regarding bias in estimates of recurrent vulvovaginal candidiasis. 61
30507400 2018
130
Curcumin-Loaded Liquid Crystalline Systems for Controlled Drug Release and Improved Treatment of Vulvovaginal Candidiasis. 61
30184431 2018
131
Influence of Nursing Intervention on Recurrent Vulvovaginal Candidiasis Patients Treated with ATP-infrared Bio-effect Technique. 61
30524981 2018
132
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. 61
29975334 2018
133
Burden of fungal infections in Iran. 61
32004161 2018
134
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. 61
29553834 2018
135
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis. 61
30359236 2018
136
Adhesion and biofilm formation of Candida parapsilosis isolated from vaginal secretions to copper intrauterine devices. 61
30365642 2018
137
An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis. 61
30384449 2018
138
Amphotericin B-Loaded Poly(lactic-co-glycolic acid) Nanofibers: An Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. 61
29940181 2018
139
Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. 61
29517833 2018
140
Effect of pea protein plus grape seed dry extract on a murine model of Candida albicans induced vaginitis. 61
30256168 2018
141
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. 61
29775695 2018
142
In vitro probiotic properties of vaginal Lactobacillus fermentum MG901 and Lactobacillus plantarum MG989 against Candida albicans. 61
30014929 2018
143
Prevalence and antifungal susceptibility of Candida species among pregnant women attending a school maternity at Natal, Brazil. 61
29908032 2018
144
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. 61
30235387 2018
145
The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review. 61
30145093 2018
146
Analysis of the Vaginal Microecological Status and Genital Tract Infection Characteristics of 751 Pregnant Women. 61
30065240 2018
147
Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. 61
30074004 2018
148
Culture Supernatants of Lactobacillus gasseri and L. crispatus Inhibit Candida albicans Biofilm Formation and Adhesion to HeLa Cells. 61
29603066 2018
149
Association of gestational diabetes mellitus and abnormal vaginal flora with adverse pregnancy outcomes. 61
30142788 2018
150
Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B. 61
29497926 2018
151
Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents. 61
29674635 2018
152
Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals. 61
29136186 2018
153
Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. 61
29637269 2018
154
Changing virulence factors among vaginal non-albicans Candida species. 61
30429388 2018
155
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. 61
29874389 2018
156
In Vivo Vaginal Fungal Load Reduction After Treatment with Itraconazole-Loaded Polycaprolactone-Nanoparticles. 61
29944108 2018
157
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. 61
30052917 2018
158
Detection of Candida species in pregnant Chinese women with a molecular beacon method. 61
29676728 2018
159
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. 61
29902998 2018
160
[Vulvovaginal candidiasis in pregnant women in the Mère et Enfant Hospital center in Nouakchott, Mauritania]. 61
29548876 2018
161
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. 61
29932786 2018
162
Vaginal antimycotics and the risk for spontaneous abortions. 61
29510088 2018
163
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. 61
29697770 2018
164
In Vitro Probiotic Properties of Lactobacillus salivarius MG242 Isolated from Human Vagina. 61
28861766 2018
165
Anticandidal synergistic activity of Ocimum sanctum and fluconazole of azole resistance strains of clinical isolates. 61
29730129 2018
166
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. 61
29697768 2018
167
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. 61
29534874 2018
168
Candida vaginitis: virulence, host response and vaccine prospects. 61
29538739 2018
169
Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant Candida albicans. 61
29549835 2018
170
Burden of Serious Fungal Infections in Argentina. 61
29695056 2018
171
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. 61
29340981 2018
172
Antifungal effects of ethanolic and aqueous extracts of Vitexagnus-castus against vaginal isolates of Candida albicans. 61
30186986 2018
173
Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. 61
28939305 2018
174
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". 61
29203543 2018
175
Burden of Severe Fungal Infections in Burkina Faso. 61
29534500 2018
176
Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. 61
29537451 2018
177
The Burden of Fungal Diseases in Romania. 61
29494484 2018
178
An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan. 61
29518045 2018
179
Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. 61
30186987 2018
180
Vaginitis: Diagnosis and Treatment. 61
29671516 2018
181
Anti-inflammatory effect of two Lactobacillus strains during infection with Gardnerella vaginalis and Candida albicans in a HeLa cell culture model. 61
29458690 2018
182
Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications. 61
29434708 2018
183
High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans. 61
28920516 2018
184
Propolis increases neutrophils response against Candida albicans through the increase of reactive oxygen species. 61
29302986 2018
185
Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa. 61
29109176 2018
186
An Estimate of the Burden of Fungal Disease in Norway. 61
29466284 2018
187
Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device. 61
27957732 2018
188
A Comprehensive in Silico Analysis of Regulatory SNPs of Human CLEC7A Gene and Its Validation as Genotypic and Phenotypic Disease Marker in Recurrent Vulvovaginal Infections. 61
29616193 2018
189
Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. 61
29628769 2018
190
The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future. 61
29755472 2018
191
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. 61
28987021 2018
192
Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration. 61
30063729 2018
193
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. 61
29977925 2018
194
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. 61
29850562 2018
195
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. 61
29619437 2018
196
IL-9 Integrates the Host-Candida Cross-Talk in Vulvovaginal Candidiasis to Balance Inflammation and Tolerance. 61
30515173 2018
197
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. 61
30425538 2018
198
Natural Products for Vulvovaginal Candidiasis Treatment: Evidence from Clinical Trials. 61
30277156 2018
199
Burden of Serious Fungal Infections in Jordan. 61
29371507 2018
200
[Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database]. 61
29183654 2018
201
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. 61
29963049 2018
202
The Role of Polymorphonuclear Leukocyte Counts from Urethra, Cervix, and Vaginal Wet Mount in Diagnosis of Nongonococcal Lower Genital Tract Infection. 61
30147292 2018
203
A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections. 61
30538510 2018
204
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. 61
29364495 2018
205
Inhibition of CXCR4 by MicroRNA-1192 Reduces the Activation of Th17 Cells and Expression of Inflammation Factors in a Mouse Model of Vulvovaginal Candidiasis. 61
30355939 2018
206
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. 61
28986195 2018
207
Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: A non-targeted LC-MS pilot study. 61
30133508 2018
208
Peptidomic Analysis of Female Reproductive Tract Secretion to Identify Putative Anti-Infection Peptides in the Female Genital System via Nanotechnologies. 61
29463379 2018
209
Streptococcus agalactiae Inhibits Candida albicans Hyphal Development and Diminishes Host Vaginal Mucosal TH17 Response. 61
29527193 2018
210
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species. 61
29681727 2018
211
Novel Intravaginal Drug Delivery System Based on Molecularly PEGylated Lipid Matrices for Improved Antifungal Activity of Miconazole Nitrate. 61
29977910 2018
212
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. 61
28867602 2017
213
Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article. 61
29354612 2017
214
Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. 61
29707675 2017
215
Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care. 61
29158246 2017
216
Evaluation of esterase and hemolysin activities of different Candida species isolated from vulvovaginitis cases in Lorestan Province, Iran. 61
29707672 2017
217
NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans. 61
29259175 2017
218
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. 61
28760590 2017
219
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. 61
28844452 2017
220
Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. 61
27170259 2017
221
Candida and its dual lifestyle as a commensal and a pathogen. 61
28263903 2017
222
In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp. 61
28826987 2017
223
[Effect of chloroform extracts from Longdan Xiegan decoction in inhibiting hydrolytic enzyme activity of Candida albicans isolated from VVC patients]. 61
29271161 2017
224
Probiotics for vulvovaginal candidiasis in non-pregnant women. 61
29168557 2017
225
Management of chronic vulvovaginal candidiasis: a long term retrospective study. 61
27250078 2017
226
Recurrent vulvovaginal candidiasis: A review of guidelines and recommendations. 61
28967688 2017
227
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? 61
28868834 2017
228
Overexpression of Candida albicans Secreted Aspartyl Proteinase 2 or 5 Is Not Sufficient for Exacerbation of Immunopathology in a Murine Model of Vaginitis. 61
28760935 2017
229
Novel Pemulen/Pullulan blended hydrogel containing clotrimazole-loaded cationic nanocapsules: Evaluation of mucoadhesion and vaginal permeation. 61
28629093 2017
230
Identification of Candida species in vaginal flora using conventional and molecular methods. 61
28578925 2017
231
Control of Mucosal Candidiasis in the Zebrafish Swim Bladder Depends on Neutrophils That Block Filament Invasion and Drive Extracellular-Trap Production. 61
28607100 2017
232
Recurrent vulvovaginal candidiasis. 61
28927765 2017
233
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. 61
28811858 2017
234
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. 61
28419509 2017
235
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. 61
28911197 2017
236
Prevalence of Candida africana and Candida dubliniensis, in vulvovaginal candidiasis: First Turkish Candida africana isolates from vulvovaginal candidiasis. 61
28641919 2017
237
Exoenzyme activity and possibility identification of Candida dubliniensis among Candida albicans species isolated from vaginal candidiasis. 61
28642006 2017
238
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. 61
28696240 2017
239
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? 61
28730269 2017
240
Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. 61
28645176 2017
241
A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. 61
27838642 2017
242
Vaginal Candida spp. genomes from women with vulvovaginal candidiasis. 61
28582496 2017
243
Cell damage caused by vaginal Candida albicans isolates from women with different symptomatologies. 61
28771140 2017
244
Screening of vulvovaginal infections during pregnancy in resource constrained settings: Implications on preterm delivery. 61
27422139 2017
245
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. 61
28611859 2017
246
Serious fungal infections in Portugal. 61
28188492 2017
247
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis 61
28688376 2017
248
Clinical Validation of a Test for the Diagnosis of Vaginitis. 61
28594779 2017
249
Comparison of enzymatic activities in different Candida species isolated from women with vulvovaginitis. 61
28236530 2017
250
Vaginitis: Beyond the Basics. 61
28499528 2017
251
Fenticonazole: an effective topical treatment for superficial mycoses as the first-step of antifungal stewardship program. 61
28678309 2017
252
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. 61
28299831 2017
253
Serious fungal infections in Thailand. 61
28161742 2017
254
[The burden of fungal infections in Algeria]. 61
28342778 2017
255
Serious fungal diseases in the Republic of Uzbekistan. 61
28293759 2017
256
Burden of fungal infections in Algeria. 61
28220323 2017
257
Serious fungal infections in Canada. 61
28161745 2017
258
Burden of serious fungal infections in Guatemala. 61
28243758 2017
259
Serious fungal infections in Chile. 61
28188493 2017
260
Serious fungal infections in Egypt. 61
28213689 2017
261
Serious fungal infections in the Philippines. 61
28220322 2017
262
Recurrent vulvovaginal candidiasis. 61
28615397 2017
263
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. 61
28314677 2017
264
Silk textile with antimicrobial AEM5772/5 (Dermasilk): a pilot study with positive influence on acne vulgaris on the back. 61
28239832 2017
265
Is uncertain vulvovaginal candidiasis a marker of vulvodynia? A study in a Dutch general practice research database. 61
30564664 2017
266
Development of a real-time PCR assay for the direct detection of Candida species causing Vulvovaginal candidiasis. 61
28242128 2017
267
In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. 61
28158577 2017
268
Efficacy of vitamin B complex as an adjuvant therapy for the treatment of complicated vulvovaginal candidiasis: An in vivo and in vitro study. 61
28157653 2017
269
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. 61
28066940 2017
270
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. 61
28385421 2017
271
New developments and directions in the clinical application of the echinocandins. 61
28180946 2017
272
Comment on treatment for recurrent vulvovaginal candidiasis. 61
27865976 2017
273
The effect of vaginal cream containing ginger in users of clotrimazole vaginal cream on vaginal candidiasis. 61
28516061 2017
274
Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis. 61
27882525 2017
275
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. 61
28299777 2017
276
[Vulvovaginal candidiasis: An old disease with new challenges]. 61
28431891 2017
277
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. 61
28511380 2017
278
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association with clinical findings. 61
28052314 2017
279
A clinical study of cutaneous changes in pregnancy. 61
27870929 2017
280
Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis. 61
28292981 2017
281
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans. 61
28105725 2017
282
Antifungal effects of Lavandula binaludensis and Cuminum cyminum essential oils against Candida albicans strains isolated from patients with recurrent vulvovaginal candidiasis. 61
27751723 2017
283
Lactobacillus crispatus Modulates Vaginal Epithelial Cell Innate Response to Candida albicans. 61
28139509 2017
284
Genetic and Phenotypic Screening of Mannose-Binding Lectin in Relation to Risk of Recurrent Vulvovaginal Infections in Women of North India: A Prospective Cohort Study. 61
28197138 2017
285
Epidemiology and clinico-investigative study of organisms causing vaginal discharge. 61
28442807 2017
286
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model. 61
28831255 2017
287
Corrigendum to "Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis". 61
29279857 2017
288
pH-Dependant Antifungal Activity of Valproic Acid against the Human Fungal Pathogen Candida albicans. 61
29062309 2017
289
Virulence factors and genetic variability of vaginal Candida albicans isolates from HIV-infected women in the post-highly active antiretroviral era. 61
28793015 2017
290
Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. 61
27756539 2017
291
Vaginal Infections in Haitian Immigrant Women Living in Miami, Florida. 61
28804083 2017
292
Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis. 61
27435998 2017
293
Development and Characterization of Nisin Nanoparticles as Potential Alternative for the Recurrent Vaginal Candidiasis Treatment. 61
26810491 2016
294
Baofukang suppository promotes the repair of vaginal epithelial cells in response to Candida albicans. 61
27830496 2016
295
Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species. 61
28491253 2016
296
Overexpression of MDR-1 and CDR-2 genes in fluconazole resistance of Candida albicans isolated from patients with vulvovaginal candidiasis. 61
28959792 2016
297
The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. 61
27741168 2016
298
Prevalence and Correlates of Genital Infections Among Newly Diagnosed Human Immunodeficiency Virus-Infected Adults Entering Human Immunodeficiency Virus Care in Windhoek, Namibia. 61
27893600 2016
299
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. 61
26690853 2016
300
[Relationship of HPV infection and BV, VVC, TV: a clinical study based on 1 261 cases of gynecologic outpatients]. 61
27788738 2016
301
[Study on the production of IgG derived from vaginal epithelial cells and the effect of anti-Candida albicans]. 61
27788740 2016
302
A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates. 61
27431223 2016
303
High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study. 61
27435791 2016
304
Distribution and Drug Susceptibility of Candida spp. Associated With Female Genital Tract Infection, Chongqing, China. 61
28138369 2016
305
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). 61
27393491 2016
306
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. 61
27480852 2016
307
Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus. 61
27298383 2016
308
Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months. 61
27206514 2016
309
Phospholipase and proteinase activities of Candida spp. isolates from vulvovaginitis in Iran. 61
27544321 2016
310
Inhalant allergy compounding the chronic vaginitis syndrome: characterization of sensitization patterns, comorbidities and responses to sublingual immunotherapy. 61
27040422 2016
311
Is human Dectin-1 Y238X gene polymorphism related to susceptibility to recurrent vulvovaginal candidiasis? 61
28681024 2016
312
Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment. 61
27556451 2016
313
Microsatellite analysis of genotype distribution patterns of Candida albicans vulvovaginal candidiasis in Nanjing, China and its association with pregnancy, age and clinical presentation. 61
26861467 2016
314
[Effects of antimicrobial peptide LL-37 expressed and purified from prokaryotes in the murine model of vaginal candidiasis]. 61
27465873 2016
315
Selection of Lactobacillus strains as potential probiotics for vaginitis treatment. 61
27154285 2016
316
The Effects of Ozonated Olive Oil and Clotrimazole Cream for Treatment of Vulvovaginal Candidiasis. 61
27548492 2016
317
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. 61
27073145 2016
318
A prospective observational study of vulvovagintis in pregnant women in Argentina, with special reference to candidiasis. 61
26931504 2016
319
Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. 61
27304096 2016
320
Candida nivariensis as a New Emergent Agent of Vulvovaginal Candidiasis: Description of Cases and Review of Published Studies. 61
26708316 2016
321
Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals. 61
26468549 2016
322
Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. 61
27218592 2016
323
Species Distribution and In Vitro Antifungal Susceptibility of Vulvovaginal Candida Isolates in China. 61
27174323 2016
324
Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis. 61
26883592 2016
325
Fluconazole use and birth defects in the National Birth Defects Prevention Study. 61
26640069 2016
326
Effect of norfloxacin therapy for acute, uncomplicated lower urinary tract infection on vaginal Candida prevalence. 61
26564224 2016
327
Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns. 61
27552787 2016
328
Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. 61
26991298 2016
329
Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. 61
27129474 2016
330
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. 61
26767080 2016
331
Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. 61
26627336 2016
332
[Pulsatilla decoction inhibits vulvovaginal Candida albicans proliferation and reduces inflammatory cytokine levels in vulvovaginal candidiasis mice]. 61
26927371 2016
333
[Longitudinal analysis of vaginal microbiota in women with recurrent vulvovaginal candidiasis]. 61
28219862 2016
334
Comorbidities Among Women With Vulvovaginal Complaints in Family Practice. 61
26782608 2016
335
ALS1 and ALS3 gene expression and biofilm formation in Candida albicans isolated from vulvovaginal candidiasis. 61
27376044 2016
336
High Virulence and Antifungal Resistance in Clinical Strains of Candida albicans. 61
28058052 2016
337
Burden of serious fungal infections in the Dominican Republic. 61
26027476 2016
338
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. 61
27915337 2016
339
Recurrent vulvovaginal candidiasis. 61
26164695 2016
340
Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity. 61
27415762 2016
341
Advanced topical drug delivery system for the management of vaginal candidiasis. 61
24959937 2016
342
[INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.] 61
29370489 2016
343
A Murine Model of Candida glabrata Vaginitis Shows No Evidence of an Inflammatory Immunopathogenic Response. 61
26807975 2016
344
Prevalence and antifungal susceptibility of Candida albicans and its related species Candida dubliniensis and Candida africana isolated from vulvovaginal samples in a hospital of Argentina. 61
26922471 2016
345
Curcumin: a novel non-steroidal contraceptive with antimicrobial properties. 61
26709650 2016
346
Logic regression-derived algorithms for syndromic management of vaginal infections. 61
26674351 2015
347
The dynamic changes of vaginal microecosystem in patients with recurrent vulvovaginal candidiasis: a retrospective study of 800 patients. 61
26041326 2015
348
Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. 61
26183965 2015
349
Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders. 61
25196575 2015
350
α-Amylase in Vaginal Fluid: Association With Conditions Favorable to Dominance of Lactobacillus. 61
25878210 2015
351
Does vaginal douching affect the type of candidal vulvovaginal infection? 61
26129887 2015
352
Bioadhesive vaginal drug delivery of nystatin using a derivatized polymer: Development and characterization. 61
26235393 2015
353
Phospholipase and Aspartyl Proteinase Activities of Candida Species Causing Vulvovaginal Candidiasis in Patients with Type 2 Diabetes Mellitus. 61
26032358 2015
354
Studies of Immune Responses in Candida vaginitis. 61
26473934 2015
355
Burden of serious fungal diseases in Hungary. 61
26449504 2015
356
The burden of serious fungal diseases in Russia. 61
26449508 2015
357
The burden of fungal disease in Denmark. 61
26449502 2015
358
Burden of serious fungal infections in Mexico. 61
26449505 2015
359
Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of Candida species isolated from vaginal infections. 61
26238597 2015
360
[Vulvovaginal candidiasis]. 61
26636630 2015
361
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. 61
26124165 2015
362
Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. 61
25935553 2015
363
In vitro modulation of probiotic bacteria on the biofilm of Candida glabrata. 61
26028405 2015
364
Neutrophil Gelatinase-Associated Lipocalin Concentration in Vaginal Fluid: Relation to Bacterial Vaginosis and Vulvovaginal Candidiasis. 61
25670719 2015
365
Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. 61
26137971 2015
366
Antifungal activity of clotrimazole against Candida albicans depends on carbon sources, growth phase and morphology. 61
25976001 2015
367
Vulvovaginal Candidiasis in Aminu Kano Teaching Hospital, North-West Nigeria: Hospital-Based Epidemiological Study. 61
26229716 2015
368
Phenotypic characterization and adhesive properties of vaginal Candida spp. strains provided by the CHU Farhat Hached (Sousse, Tunisia). 61
25618183 2015
369
Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. 61
25887336 2015
370
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. 61
25877666 2015
371
Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. 61
25526757 2015
372
Estimated Burden of Serious Fungal Infections in Jamaica by Literature Review and Modelling. 61
26426178 2015
373
Vulvovaginal candidiasis in pregnancy. 61
25916994 2015
374
New signaling pathways govern the host response to C. albicans infection in various niches. 61
25858952 2015
375
Cellular Structural Changes in Candida albicans Caused by the Hydroalcoholic Extract from Sapindus saponaria L. 61
26007191 2015
376
Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis-causing Candida glabrata isolates. 61
25688886 2015
377
Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. 61
25052208 2015
378
Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. 61
25724389 2015
379
Diverse nitrogen sources in seminal fluid act in synergy to induce filamentous growth of Candida albicans. 61
25662979 2015
380
Diagnostic Value of Vaginal Discharge, Wet Mount and Vaginal pH - An Update on the Basics of Gynecologic Infectiology. 61
26028693 2015
381
Identification of cytolytic vaginosis versus vulvovaginal candidiasis. 61
25279977 2015
382
The Comparison of vaginal cream of mixing yogurt, honey and clotrimazole on symptoms of vaginal candidiasis. 61
26153168 2015
383
Isolation of different species of Candida in patients with vulvovaginal candidiasis from sari, iran. 61
26034533 2015
384
Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. 61
25596116 2015
385
Transcriptomic analysis of vulvovaginal candidiasis identifies a role for the NLRP3 inflammasome. 61
25900651 2015
386
[Diversity of Lactobacillus in vagina of vulvovaginal candidiasis]. 61
26506713 2015
387
Treatment of vaginal candidiasis for the prevention of preterm birth: a systematic review and meta-analysis. 61
25874659 2015
388
Dynamical evaluation of vaginal micro-ecosystem in a Chinese woman with recurrent vulvovaginal candidiasis. 61
25867410 2015
389
Candidiasis (vulvovaginal). 61
25775428 2015
390
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. 61
26001874 2015
391
Can intrauterine contraceptive devices lead to VulvoVaginal Candidiasis (VVC) and Anemia in Iranian new users? 61
25637424 2015
392
Humoral immune responses to Candida albicans complement receptor 3-related protein in the atopic subjects with vulvovaginal candidiasis. Novel sensitive marker for Candida infection. 61
25673750 2015
393
Effect of highly active antiretroviral therapy on vaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women. 61
25923898 2015
394
Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. 61
25534676 2015
395
CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans. 61
25547797 2015
396
Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis. 61
25322705 2015
397
[Vaginal infections in a Family Health Clinic in the Metropolitan Region, Chile]. 61
25860041 2015
398
[Inhibitory effects of butyl alcohol extract of Baitouweng decoction on yeast-to-hyphae transition of Candida albicans isolates from VVC in alkaline pH environment]. 61
26137695 2015
399
Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. 61
25416649 2015
400
Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation. 61
26267119 2015
401
Liquid crystal precursor mucoadhesive system as a strategy to improve the prophylactic action of Syngonanthus nitens (Bong.) Ruhland against infection by Candida krusei. 61
26719688 2015
402
Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. 61
25720546 2015
403
Comment on "Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition". 61
24769654 2015
404
Reply to Dr. Reichman's comments on "Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition". 61
24769655 2015
405
Treatment of vulvovaginal candidiasis: a review of the literature. 61
25770305 2015
406
Microbicidal activity of neutrophils is inhibited by isolates from recurrent vaginal candidiasis (RVVC) caused by Candida albicans through fungal thioredoxin reductase. 61
25497972 2015
407
Molecular Characterization of Candida africana in Genital Specimens in Shanghai, China. 61
26665002 2015
408
Chronic vulvovaginal Candida hypersensitivity: An underrecognized and undertreated disorder by allergists. 61
25860170 2015
409
Candidiasis: a fungal infection--current challenges and progress in prevention and treatment. 61
25809621 2015
410
Vulval pruritus: the experience of gynaecologists revealed by biopsy. 61
25010568 2015
411
Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans. 61
24071640 2015
412
Nanostructured lipid system as a strategy to improve the anti-Candida albicans activity of Astronium sp. 61
26300640 2015
413
Propolis Is an Efficient Fungicide and Inhibitor of Biofilm Production by Vaginal Candida albicans. 61
25815029 2015
414
Genetic variability of Candida albicans Sap8 propeptide in isolates from different types of infection. 61
25734055 2015
415
Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda. 61
26594637 2015
416
Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms. 61
25367916 2015
417
Changes in vaginal microbiota following antimicrobial and probiotic therapy. 61
26282697 2015
418
[Yeast species in vulvovaginitis candidosa]. 61
25544052 2015
419
The Absence of N-Acetyl-D-glucosamine Causes Attenuation of Virulence of Candida albicans upon Interaction with Vaginal Epithelial Cells In Vitro. 61
26366412 2015
420
Detection of phospholipase activity of Candida albicans and non albicans isolated from women of reproductive age with vulvovaginal candidiasis in rural area. 61
25560009 2015
421
In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. 61
25442913 2014
422
Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. 61
25544891 2014
423
Probiotic Properties of Lactobacillus crispatus 2,029: Homeostatic Interaction with Cervicovaginal Epithelial Cells and Antagonistic Activity to Genitourinary Pathogens. 61
25028263 2014
424
Management of persistent vaginitis. 61
25415165 2014
425
Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. 61
25305660 2014
426
Effect of progesterone on Candida albicans vaginal pathogenicity. 61
25183575 2014
427
Comparison Between Virulence Factors of Candida albicans and Non-Albicans Species of Candida Isolated from Genitourinary Tract. 61
25584218 2014
428
Genetic relatedness among vaginal and anal isolates of Candida albicans from women with vulvovaginal candidiasis in north-east Brazil. 61
25187602 2014
429
Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study. 61
25291115 2014
430
Recurrent vulvovaginitis. 61
25220102 2014
431
Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. 61
25005365 2014
432
Dermatosis associated with menopause. 61
25540566 2014
433
Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis. 61
25118875 2014
434
The role of Human Dectin-1 Y238X Gene Polymorphism in recurrent vulvovaginal candidiasis infections. 61
25008994 2014
435
Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. 61
24962255 2014
436
Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India. 61
24697839 2014
437
The impact of vulvar lichen sclerosus on sexual dysfunction. 61
25162790 2014
438
Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. 61
25023482 2014
439
Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains. 61
24798281 2014
440
[Place of vulvovaginal candidiasis in the lower genital tract infections and associated risk factors among women in Benin]. 61
24746421 2014
441
Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. 61
24746725 2014
442
Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan (Cote d'Ivoire). 61
24387809 2014
443
Phenotypic Characterization and Antifungal Susceptibility Pattern to Fluconazole in Candida species Isolated from Vulvovaginal Candidiasis in a Tertiary Care Hospital. 61
24995172 2014
444
Factors Associated with Symptomatic Vulvovaginal Candidiasis: A Study among Women Attending a Primary Healthcare Clinic in Kwazulu-Natal, South Africa. 61
24971218 2014
445
Formulation and in vitro evaluation of coconut oil-core cationic nanocapsules intended for vaginal delivery of clotrimazole. 61
24503350 2014
446
Lack of evidence for sexual transmission of genital Candida species among women who have sex with women: a mixed methods study. 61
24431188 2014
447
The effects of oral garlic on vaginal candida colony counts: a randomised placebo controlled double-blind trial. 61
24308540 2014
448
Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. 61
24612727 2014
449
Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). 61
24410011 2014
450
Co-occurrence of Trichomonas vaginalis and bacterial vaginosis and vaginal shedding of HIV-1 RNA. 61
24521723 2014
451
Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. 61
24478069 2014
452
Is antibiotic prophylaxis necessary before midurethral sling procedures for female stress incontinence? A decision analysis. 61
23903818 2014
453
Vaginal epithelial cell-derived S100 alarmins induced by Candida albicans via pattern recognition receptor interactions are sufficient but not necessary for the acute neutrophil response during experimental vaginal candidiasis. 61
24478092 2014
454
Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. 61
25110589 2014
455
[Vaginal colonization by Candida spp. Frequency and description of the species isolated in asymptomatic women]. 61
24701855 2014
456
Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. 61
24186907 20